Form 4 for DNA Ginkgo Bioworks Holdings, Inc.
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-13 · accession 0001127602-25-009690 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-17 | 2025-03-13 | DNA | Dmytruk Mark E. | See remarks | C - Cnv Deriv | $0.00 | +9,497 | 44.1K | +27% | $0 |
| D | 2025-03-17 | 2025-03-13 | DNA | Dmytruk Mark E. | See remarks | C - Cnv Deriv | $0.00 | -9,497 | 5,914 | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-03-13 | C | A | 9,497 | $0.00 | 44,149 | D | — | — | |
| 2 | Derivative | Class B Common Stock | 2025-03-13 | C | D | 9,497 | $0.00 | 5,914 | D | — · — to — | 9,497 Class A Common Stock | (F2) Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. |